Leadership Team

Therapure Biopharma Inc. is led by an experienced team of life sciences professionals who bring a broad range of experience to all of our projects:

Nicholas Green, BSc, MBA

President and Chief Executive Officer

Nick has more than 25 years of experience in the industry. Since starting his career in a family-owned business, Nick has held a number of senior management roles, most notably Managing Director of Nipa Laboratories Ltd., Head of the Life Science Division of Clariant International Ltd. in the USA, President and CEO of Rhodia Pharma Solutions Ltd. and President of Codexis, Inc.’s Pharma Division.

Nick holds a BSc (Hons) in Chemistry from Queen Mary College in London and an MBA from the University of Huddersfield.

David Long, MBA, CPA

Chief Financial Officer

David has over 25 years of experience in finance, having held progressively senior roles throughout his career. Most recently he was CFO of Softchoice Corporation, an IT solutions and services company serving the North American market. Prior to that, David was CFO of Tundra Semiconductor. Both Softchoice Corporation and Tundra Semiconductor were listed on the Toronto Stock Exchange at the time that David was CFO of such companies. David has spent most of his career in public companies of all sizes with operations around the world. He has a Bachelor’s degree in Management from St Francis Xavier University and an MBA in Finance from Dalhousie University. Additionally, David is a Chartered Professional Accountant (CPA/CGA).

David N. Bell, MSc, PhD

Vice President, Drug Development and Chief Scientific Officer

David's primary responsibility at Therapure is the development of a pipeline consisting of new protein and cell-culture-based product candidates for the treatment of anemia, cancer and infectious diseases. He also leads the team offering development services for new product entries. Prior to joining the company in 1994, David was Group Leader of Cancer Biology at BioChem Therapeutic, Inc. and before that, Laboratory Director of the BioVentures Division of FAA in Worcester, Massachusetts, USA.

He received his PhD from the Department of Medicine at McGill University in 1988 and completed a postdoctoral fellowship at the McGill Cancer Centre.

Dirk Alkema, BSc, PhD (Biochemistry)

Vice President, Technical Operations

Dirk oversees Therapure's clinical and commercial manufacturing operations and its biomanufacturing services. Prior to joining the company in early 1994, Dirk worked at Connaught Laboratories Ltd. where he held a number of production management positions prior to his appointment to Director, Viral Vaccine Manufacturing Division in 1989. During his tenure at Connaught, Dirk managed the plasma fractionation facility that serviced the Canadian market.

Safa'a Al-Rais, BSc, MSc, MBA

Vice President, Operations

Safa’a joined Therapure in May of 2009. In his senior leadership role, Safa’a provides direction, strategic management and accountability for Therapure’s multi-function global client programs ensuring that projects are planned and executed within a client-centric environment. Safa’a has over 12 years of combined practical and senior-level management experience in both the automotive and pharmaceutical industries where he built and led high-performance teams, successfully delivering on a number of critical and challenging projects.

PAUL STOJANOVSKI, BSC, C CHEM

Vice President, Quality Operations

Paul joined Therapure in August of 2017 with over 30 years of Quality and Operations experience in branded, generic and CDMO pharmaceuticals. Prior to joining Therapure, Paul held senior global quality and compliance executive positions at Mylan and Teva. Throughout his career, he has worked closely with manufacturing operations, product development and supply chain to develop partnerships in alignment of quality with regulatory, client and the business to exceed patient needs. His responsibilities, held at multiple sites globally, has been to provide in-depth knowledge and working experience with regulatory agencies that include Health Canada, US FDA, ANVISA, MHRA, EMA, and TGA. Paul is ultimately responsible for ensuring regulatory compliance and overseeing the quality operations related to the development, validation, manufacturing, testing and release of products manufactured by Therapure for its clients.
Paul holds a BSc in Biochemistry and Chemistry from the University of Toronto and is a Charter Chemist of Ontario.

Rajan Puri, BSc, MSc, MBA

Vice President, Business Development

Raj joined Therapure in November 2008. He is responsible for managing the new business development efforts. Prior to joining Therapure, Rajan held senior business development positions with two different Canadian biopharmaceutical companies. Rajan started his career with Eli Lilly Canada, where he held progressively expanding positions in both regulatory affairs and product management.

Dina Iezzi

Director, Marketing & Special Projects

Prior to joining Therapure in September 2010, Dina worked for Draxis Pharma Inc. There, she held a number of director positions in various divisions of the organization, including Director of the Commercial Pharmaceutical Contract Manufacturing division. Dina started her career in the pharmaceutical industry, holding a range of positions in sales and marketing, and she led many initiatives involving medical, regulatory (FDA, EMA, Health Canada) and government affairs. Dina has extensive experience in the marketing and sales of therapeutic products, and in contract manufacturing services focused on the pharmaceutical and biotechnology industries.